Works by Siegel, David S.

Results: 56

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.

Published in:

Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00733-2

By:

Gill, Sarvarinder K.;
Unawane, Rashmi;
Wang, Shuqi;
Ahn, Jaeil;
Aleman, Adolfo;
Siegel, David S.;
Vesole, David H.;
Parmar, Harsh;
Phull, Pooja;
Biran, Noa

Publication type:

Article

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Published in:

Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00507-2

By:

Jagannath, Sundar;
Lin, Yi;
Goldschmidt, Hartmut;
Reece, Donna;
Nooka, Ajay;
Senin, Alicia;
Rodriguez-Otero, Paula;
Powles, Ray;
Matsue, Kosei;
Shah, Nina;
Anderson, Larry D.;
Streetly, Matthew;
Wilson, Kimberly;
Le, Hoa Van;
Swern, Arlene S.;
Agarwal, Amit;
Siegel, David S.

Publication type:

Article

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.

Published in:

Blood Cancer Journal, 2020, v. 10, n. 3, p. 1, doi. 10.1038/s41408-020-0300-y

By:

Dimopoulos, Meletios A.;
Niesvizky, Ruben;
Weisel, Katja;
Siegel, David S.;
Hajek, Roman;
Mateos, María-Victoria;
Cavo, Michele;
Huang, Mei;
Zahlten-Kumeli, Anita;
Moreau, Philippe

Publication type:

Article

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Published in:

Leukemia & Lymphoma, 2025, v. 66, n. 5, p. 942, doi. 10.1080/10428194.2024.2446617

By:

Varma, Gaurav;
Fogel, Lindsay;
Gordon, Beth;
Saldarriaga, Mateo Mejia;
Ahn, Jaeil;
Aleman, Adolfo;
Caro, Jessica;
Rosenberg, Maya C.;
Monge, Jorge;
Parmar, Harsh;
Kaminetzky, David;
Moskovits, Tibor;
Siegel, David S.;
Morgan, Gareth J.;
Niesvizky, Ruben;
Davies, Faith E.;
Biran, Noa

Publication type:

Article

Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.

Published in:

Leukemia & Lymphoma, 2024, v. 65, n. 13, p. 2000, doi. 10.1080/10428194.2024.2385501

By:

Zolotov, Eli;
Kabat, Maciej;
Parmar, Harsh;
Anand, Palka;
Zenreich, Joshua;
Aleman, Adolfo;
Phull, Pooja;
Doucette, Kimberly;
Vesole, David H.;
Siegel, David S.;
Biran, Noa

Publication type:

Article

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Published in:

Leukemia & Lymphoma, 2022, v. 63, n. 6, p. 1407, doi. 10.1080/10428194.2022.2030477

By:

Bahlis, Nizar J.;
Siegel, David S.;
Schiller, Gary J.;
Samaras, Christy;
Sebag, Michael;
Berdeja, Jesus;
Ganguly, Siddhartha;
Matous, Jeffrey;
Song, Kevin;
Seet, Christopher S.;
Acosta-Rivera, Mirelis;
Bar, Michael;
Quick, Donald;
Anz, Bertrand;
Fonseca, Gustavo;
Chung, Weiyuan;
Lee, Kim;
Mouro, Jorge;
Agarwal, Amit;
Reece, Donna

Publication type:

Article

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.

Published in:

2018

By:

Vesole, David H.;
Richter, Joshua;
Biran, Noa;
McBride, Laura;
Anand, Palka;
Huang, Mei;
Kumeli, Anita-Zahlten;
Klippel, Zandra;
Iskander, Karim;
Siegel, David S.

Publication type:

Case Study

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.

Published in:

Leukemia & Lymphoma, 2016, v. 57, n. 12, p. 2833, doi. 10.1080/10428194.2016.1177181

By:

Siegel, David S.;
Weisel, Katja C.;
Dimopoulos, Meletios A.;
Baz, Rachid;
Richardson, Paul;
Delforge, Michel;
Song, Kevin W.;
San Miguel, Jesus F.;
Moreau, Philippe;
Goldschmidt, Hartmut;
Cavo, Michele;
Jagannath, Sundar;
Yu, Xin;
Hong, Kevin;
Sternas, Lars;
Zaki, Mohamed;
Palumbo, Antonio

Publication type:

Article

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Published in:

Leukemia & Lymphoma, 2015, v. 56, n. 10, p. 2959, doi. 10.3109/10428194.2015.1020801

By:

Vij, Ravi;
Wang, Michael;
Jagannath, Sundar;
Niesvizky, Ruben;
Jakubowiak, Andrzej J.;
Kavalerchik, Edward;
Huang, Mei;
Siegel, David S.

Publication type:

Article

Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma.

Published in:

American Journal of Hematology, 2021, v. 96, n. 11, p. E430, doi. 10.1002/ajh.26333

By:

Biran, Noa;
Gourna Paleoudis, Elli;
Feinman, Rena;
Vesole, David H.;
Zenreich, Joshua;
Wang, Shuqi;
Ahn, Jaeil;
Bansal, Meena;
Rowley, Scott;
Donato, Michele;
Pecora, Andrew L.;
Richter, Joshua;
Anand, Palka;
McBride, Laura;
Ivanovski, Kristin;
Korngold, Robert;
Siegel, David S.

Publication type:

Article

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Published in:

American Journal of Hematology, 2021, v. 96, n. 2, p. 226, doi. 10.1002/ajh.26041

By:

Alsina, Melissa;
Landgren, Ola;
Raje, Noopur;
Niesvizky, Ruben;
Bensinger, William I.;
Berdeja, Jesus G.;
Kovacsovics, Tibor;
Vesole, David H.;
Fang, Belle;
Kimball, Amy S.;
Siegel, David S.

Publication type:

Article

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Published in:

American Journal of Hematology, 2016, v. 91, p. 400, doi. 10.1002/ajh.24300

By:

Ghobrial, Irene M.;
Siegel, David S.;
Vij, Ravi;
Berdeja, Jesus G.;
Richardson, Paul G.;
Neuwirth, Rachel;
Patel, Chirag G.;
Zohren, Fabian;
Wolf, Jeffrey L.

Publication type:

Article

P-189: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S141, doi. 10.1016/S2152-2650(21)02316-8

By:

Bahlis, Nizar J.;
Schiller, Gary J.;
Sebag, Michael;
Berdeja, Jesus G.;
Ganguly, Siddhartha;
Matous, Jeffrey V.;
Song, Kevin;
Seet, Christopher;
Acosta-Rivera, Mirelis;
Bar, Michael;
Quick, Donald;
Anz, Bertrand M.;
Fonseca, Gustavo;
Reece, Donna E.;
Vogel, Prisca;
Kim Lee;
Weiyuan Chung;
Agarwal, Amit;
Siegel, David S.

Publication type:

Article

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7

By:

Anderson, Jr., Larry D.;
Nina Shah;
Jagannath, Sundar;
Berdeja, Jesus G.;
Lonial, Sagar;
Raje, Noopur;
Siegel, David S.;
Yi Lin;
Moreau, Philippe;
Yakoub-Agha, Ibrahim;
Delforge, Michel;
Einsele, Hermann;
Goldschmidt, Hartmut;
Weisel, Katja;
Cavo, Michele;
Reece, Donna E.;
Rambaldi, Alessandro;
Truppel-Hartmann, Anna;
Patel, Payal;
Liping Huang

Publication type:

Article

OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5

By:

Lonial, Sagar;
Richardson, Paul G.;
Popat, Rakesh;
Stadtmauer, Edward A.;
Larsen, Jeremy T.;
Oriol, A.;
Knop, Stefan;
Jagannath, Sundar;
Cook, Gordon;
Badros, Ashraf Z.;
Rodríguez-Otero, Paula;
Siegel, David S.;
Tuong Vi Nguyen;
Micco, Antonia Di;
Amin, Alpesh;
Min Chen;
Kueenburg, Elisabeth;
van de Donk, Niels W.C.J.

Publication type:

Article

Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma.

Published in:

2021

By:

Richter, Joshua;
Sanchez, Larysa;
Biran, Noa;
Wang, C.K.;
Tanenbaum, Kathryn;
DeVincenzo, Victoria;
Grunman, Brooke;
Vesole, David H.;
Siegel, David S.;
Pecora, Andrew;
Goldberg, Stuart L.

Publication type:

journal article

Health-Related Quality of Life With Pomalidomide + Dexamethasone + Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e277, doi. 10.1016/j.clml.2019.09.457

By:

Reece, Donna;
Bahlis, Nizar J.;
Samaras, Christy Joy;
Sebag, Michael;
Berdeja, Jesus;
Ganguly, Siddhartha;
Matous, Jeffrey;
Song, Kevin;
Seet, Christopher S.;
Talamo, Giampaolo;
Acosta-Rivera, Mirelis;
Bar, Michael;
Quick, Donald;
Anz, Bertrand;
Fonseca, Gustavo;
Agarwal, Amit;
Chung, Weiyuan;
Zafar, Faiza;
Siegel, David S.

Publication type:

Article

Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e266, doi. 10.1016/j.clml.2019.07.299

By:

Facon, Thierry;
Niesvizky, Ruben;
Weisel, Katja;
Bringhen, Sara;
Ho, P. Joy;
Obreja, Mihaela;
Yang, Zhao;
Klippel, Zandra;
Blaedel, Julie;
Mezzi, Khalid;
Siegel, David S.

Publication type:

Article

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e118, doi. 10.1016/j.clml.2019.09.196

By:

Vogl, Dan T.;
Nooka, Ajay;
Gavriatopoulou, Maria;
Yee, Andrew;
Huff, Carol;
Moreau, Philippe;
Dingli, David;
Cole, Craig;
Richardson, Paul G.;
Dimopoulos, Meletios A.;
Lonial, Sagar;
Stewart, Keith;
Chari, Ajai;
Richter, Joshua;
Biran, Noa;
Siegel, David S.;
Liu, Jianjun;
Joshi, Anita;
Shah, Jatin;
Shacham, Sharon

Publication type:

Article

Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e117, doi. 10.1016/j.clml.2019.09.195

By:

Gavriatopoulou, Maria;
Vogl, Dan T.;
Nooka, Ajay;
Dingli, David;
Cole, Craig;
Moreau, Philippe;
Huff, Carol;
Yee, Andrew;
Dimopoulos, Meletios A.;
Lonial, Sagar;
Richardson, Paul G.;
Stewart, Keith;
Chari, Ajai;
Richter, Joshua;
Biran, Noa;
Siegel, David S.;
Liu, Jianjun;
Joshi, Anita;
Shah, Jatin;
Shacham, Sharon

Publication type:

Article

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e53, doi. 10.1016/j.clml.2019.09.081

By:

Spencer, Andrew;
Rosenberg, Aaron Seth;
Jakubowiak, Andrzej;
Raje, Noopur;
Chatterjee, Manik;
Trudel, Suzanne;
Bahlis, Nizar J.;
Siegel, David S.;
Wilop, Stefan;
Harrison, Simon J.;
NagaKrishna, Murthy;
Dhuria, Shyeilla;
Hindoyan, Antreas;
McIver, Zach;
Henary, Haby;
Morrow, Phuong Khanh;
Roberts, Andrew

Publication type:

Article

A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e52, doi. 10.1016/j.clml.2019.09.079

By:

Alsina, Melissa;
Landgren, C. Ola;
Raje, Noopur;
Niesvizky, Ruben;
Bensinger, William I.;
Berdeja, Jesus;
Kovacsovics, Tibor;
Vesole, David;
Fang, Belle;
Kimball, Amy;
Siegel, David S.

Publication type:

Article

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

Published in:

2017

By:

van Beers, Erik H.;
van Vliet, Martin H.;
Kuiper, Rowan;
de Best, Leonie;
Anderson, Kenneth C.;
Chari, Ajai;
Jagannath, Sundar;
Jakubowiak, Andrzej;
Kumar, Shaji K.;
Levy, Joan B.;
Auclair, Daniel;
Lonial, Sagar;
Reece, Donna;
Richardson, Paul;
Siegel, David S.;
Stewart, A. Keith;
Trudel, Suzanne;
Vij, Ravi;
Zimmerman, Todd M.;
Fonseca, Rafael

Publication type:

journal article

Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e141, doi. 10.1016/j.clml.2017.03.255

By:

Siegel, David S.;
Schiller, Gary J.;
Song, Kevin;
Agajanian, Richy;
Stockerl-Goldstein, Keith;
Kaya, Hakan;
Sebag, Michael;
Reu, Frederic J.;
Malek, Eshan;
Mouro, Jorge;
Chung, Weiyuan;
Srinivasan, Shankar;
Qian, Max;
Rizvi, Syed;
Thakurta, Anjan;
Bahlis, Nizar J.

Publication type:

Article

Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e142, doi. 10.1016/j.clml.2017.03.256

By:

Siegel, David S.;
Oriol, Albert;
Rajnics, Peter;
Minarik, Jiri;
Hungria, Vania;
Lee, Jae Hoon;
Song, Kevin;
Obreja, Mihaela;
Aggarwal, Sanjay;
Hajek, Roman

Publication type:

Article

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

Published in:

2016

By:

Bilotti, Elizabeth;
Vesole, David H.;
McBride, Laura;
Schmidt, Linda;
Gao, Zhijie;
Gilani, Madiha;
McNeill, Ann;
Bednarz, Urszula;
Richter, Joshua;
Mato, Anthony;
Graef, Thorsten;
Siegel, David S.

Publication type:

journal article

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Published in:

2016

By:

Siegel, David S.;
Dimopoulos, Meletios;
Jagannath, Sundar;
Goldschmidt, Hartmut;
Durrant, Simon;
Kaufman, Jonathan L.;
Leleu, Xavier;
Nagler, Arnon;
Offner, Fritz;
Graef, Thorsten;
Eid, Joseph E.;
Houp, Jennifer;
Gause, Christine;
Vuocolo, Scott;
Anderson, Kenneth C.

Publication type:

journal article

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.

Published in:

2016

By:

Jurczyszyn, Artur;
Olszewska-Szopa, Magdalena;
Vesole, Adam S.;
Vesole, David H.;
Siegel, David S.;
Richardson, Paul G.;
Paba-Prada, Claudia;
Callander, Natalie S.;
Huras, Hubert;
Skotnicki, Aleksander B.

Publication type:

journal article

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2014, v. 14, n. 1, p. e39, doi. 10.1016/j.clml.2013.09.012

By:

Wang, Trent P.;
Safran, Steven G.;
Richter, Joshua R.;
Siegel, David S.;
Vesole, David H.

Publication type:

Article

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 5, p. 310, doi. 10.1016/j.clml.2012.08.003

By:

Jagannath, Sundar;
Vij, Ravi;
Stewart, A. Keith;
Trudel, Suzanne;
Jakubowiak, Andrzej J.;
Reiman, Tony;
Somlo, George;
Bahlis, Nizar;
Lonial, Sagar;
Kunkel, Lori A.;
Wong, Alvin;
Orlowski, Robert Z.;
Siegel, David S.

Publication type:

Article

Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 3, p. 186, doi. 10.1016/j.clml.2012.01.004

By:

Tufail, Madiha;
Siegel, David S.;
McBride, Laura;
Bilotti, Elizabeth;
Bello, Erica;
Anand, Palka;
Olivo, Karly;
Bendarz, Urszula;
McNeill, Ann;
Vesole, David H.

Publication type:

Article

The Current Status and Future of Multiple Myeloma in the Clinic.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. E1, doi. 10.3816/CLM.2010.n.005

By:

Jagannath, Sundar;
Kyle, Robert A.;
Palumbo, Antonio;
Siegel, David S.;
Cunningham, Sonia;
Berenson, James

Publication type:

Article

The Current Status and Future of Multiple Myeloma in the Clinic.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. 28, doi. 10.3816/CLML.2010.n.003

By:

Jagannath, Sundar;
Kyle, Robert A.;
Palumbo, Antonio;
Siegel, David S.;
Cunningham, Sonia;
Berenson, James

Publication type:

Article

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States.

Published in:

Patient Preference & Adherence, 2022, v. 16, p. 573, doi. 10.2147/PPA.S345906

By:

Auclair, Daniel;
Mansfield, Carol;
Fiala, Mark A;
Chari, Ajai;
Cole, Craig E;
Kaufman, Jonathan L;
Orloff, Gregory J;
Siegel, David S;
Zonder, Jeffrey A;
Mange, Brennan;
Yesil, Jennifer;
Dalal, Mehul;
Mikhael, Joseph R

Publication type:

Article

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

Published in:

European Journal of Haematology, 2017, v. 99, n. 3, p. 199, doi. 10.1111/ejh.12903

By:

Moreau, Philippe;
Dimopoulos, Meletios A.;
Richardson, Paul G.;
Siegel, David S.;
Cavo, Michele;
Corradini, Paolo;
Weisel, Katja;
Delforge, Michel;
O'Gorman, Peter;
Song, Kevin;
Chen, Christine;
Bahlis, Nizar;
Oriol, Albert;
Hansson, Markus;
Kaiser, Martin;
Anttila, Pekka;
Raymakers, Reinier;
Joao, Cristina;
Cook, Gordon;
Sternas, Lars

Publication type:

Article

Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.

Published in:

2021

By:

Martin, Thomas G.;
Shah, Nina;
Richter, Joshua;
Vesole, David H.;
Wong, Sandy W.;
Huang, Chiung‐Yu;
Madduri, Deepu;
Jagannath, Sundar;
Siegel, David S.;
Biran, Noa;
Wolf, Jeffrey L.;
Parekh, Samir;
Cho, Hearn J.;
Munster, Pamela;
Richard, Shambavi;
Ziti‐Ljajic, Samira;
Chari, Ajai;
Huang, Chiung-Yu;
Ziti-Ljajic, Samira

Publication type:

journal article

Hypercalcaemia and increased serum interleukin-6 levels induced by all- trans retinoic acid in patients with multiple myeloma.

Published in:

British Journal of Haematology, 1995, v. 89, n. 1, p. 217, doi. 10.1111/j.1365-2141.1995.tb08936.x

By:

Niesvizky, Ruben;
Siegel, David S.;
Busquets, Xavier;
Nichols, Gwen;
Muindi, Josephia;
Warrell, Raymond P.;
Michaeli, Joseph

Publication type:

Article

Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients.

Published in:

European Journal of Haematology, 2025, v. 114, n. 3, p. 500, doi. 10.1111/ejh.14343

By:

Zolotov, Eli;
Patel, Vanisha;
Weiss, Yedidyah;
Biran, Noa;
Phull, Pooja;
Vesole, David H.;
Siegel, David S.;
Parmar, Harsh

Publication type:

Article

Immune tolerance with combined allogeneic haplo‐identical haematopoietic stem cell transplant and renal transplant.

Published in:

British Journal of Haematology, 2021, v. 194, n. 4, p. 779, doi. 10.1111/bjh.17540

By:

Doucette, Kimberley;
Shah, Neil J.;
Donato, Michele L.;
Siegel, David S.;
Rowley, Scott D.;
Vesole, David H.

Publication type:

Article

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.

Published in:

British Journal of Haematology, 2020, v. 188, n. 4, p. 501, doi. 10.1111/bjh.16213

By:

Siegel, David S.;
Schiller, Gary J.;
Song, Kevin W.;
Agajanian, Richy;
Stockerl‐Goldstein, Keith;
Kaya, Hakan;
Sebag, Michael;
Samaras, Christy;
Malek, Ehsan;
Talamo, Giampaolo;
Seet, Christopher S.;
Mouro, Jorge;
Pierceall, William E.;
Zafar, Faiza;
Chung, Weiyuan;
Srinivasan, Shankar;
Agarwal, Amit;
Bahlis, Nizar J.

Publication type:

Article

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study.

Published in:

British Journal of Haematology, 2019, v. 186, n. 5, p. e117, doi. 10.1111/bjh.15946

By:

Mateos, Maria‐Victoria;
Orlowski, Robert Z.;
Ocio, Enrique M.;
Rodríguez‐Otero, Paula;
Reece, Donna;
Moreau, Philippe;
Munshi, Nikhil;
Avigan, David E.;
Siegel, David S.;
Ghori, Razi;
Farooqui, Mohammed Z. H.;
Marinello, Patricia;
San-Miguel, Jesus

Publication type:

Article

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013.

Published in:

British Journal of Haematology, 2019, v. 186, n. 3, p. e41, doi. 10.1111/bjh.15888

By:

Ribrag, Vincent;
Avigan, David E.;
Green, Damian J.;
Wise‐Draper, Trisha;
Posada, Juan G.;
Vij, Ravi;
Zhu, Ying;
Farooqui, Mohammed Z. H.;
Marinello, Patricia;
Siegel, David S.

Publication type:

Article

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Published in:

British Journal of Haematology, 2018, v. 180, n. 6, p. 821, doi. 10.1111/bjh.15058

By:

Richardson, Paul G.;
Bensinger, William I.;
Huff, Carol Ann;
Costello, Caitlin L.;
Lendvai, Nikoletta;
Berdeja, Jesus G.;
Anderson Jr., Larry D.;
Siegel, David S.;
Lebovic, Daniel;
Jagannath, Sundar;
Laubach, Jacob P.;
Stockerl-Goldstein, Keith E.;
Long Kwei;
Fong Clow;
Elias, Laurence;
Zeena, Zeena;
Graef, Thorsten;
Bilotti, Elizabeth;
Vij, Ravi

Publication type:

Article

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.

Published in:

British Journal of Haematology, 2017, v. 176, n. 3, p. 440, doi. 10.1111/bjh.14429

By:

Sanchez, Larysa;
Vesole, David H.;
Richter, Joshua R.;
Biran, Noa;
Bilotti, Elizabeth;
McBride, Laura;
Anand, Palka;
Ivanovski, Kristin;
Siegel, David S.

Publication type:

Article

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Published in:

British Journal of Haematology, 2015, v. 171, n. 1, p. 52, doi. 10.1111/bjh.13517

By:

Vesole, David H.;
Bilotti, Elizabeth;
Richter, Joshua R.;
McNeill, Ann;
McBride, Laura;
Raucci, Laura;
Anand, Palka;
Bednarz, Urszula;
Ivanovski, Kristin;
Smith, Judith;
Batra, Veena;
Aleman, Adolfo;
Sims, Taliah;
Guerrero, Laura;
Mato, Anthony;
Siegel, David S.

Publication type:

Article

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Published in:

British Journal of Haematology, 2012, v. 158, n. 6, p. 739, doi. 10.1111/j.1365-2141.2012.09232.x

By:

Vij, Ravi;
Siegel, David S.;
Jagannath, Sundar;
Jakubowiak, Andrzej J.;
Stewart, Alexander Keith;
McDonagh, Kevin;
Bahlis, Nizar;
Belch, Andrew;
Kunkel, Lori A.;
Wear, Sandra;
Wong, Alvin F.;
Wang, Michael

Publication type:

Article

Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03.

Published in:

British Journal of Haematology, 2011, v. 155, n. 3, p. 340, doi. 10.1111/j.1365-2141.2011.08849.x

By:

Jacobus, Susanna J.;
Kumar, Shaji;
Uno, Hajime;
Van Wier, Scott A.;
Ahmann, Greg J.;
Henderson, Kimberly J.;
Callander, Natalie S.;
Williams, Michael E.;
Siegel, David S.;
Greipp, Philip R.;
Rajkumar, S. Vincent;
Fonseca, Rafael

Publication type:

Article

Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.

Published in:

PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0125995

By:

Zhang, Wenting;
Gu, Yexin;
Sun, Qiaoling;
Siegel, David S.;
Tolias, Peter;
Yang, Zheng;
Lee, Woo Y.;
Zilberberg, Jenny

Publication type:

Article

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Published in:

American Health & Drug Benefits, 2015, v. 8, n. 4, p. 204

By:

Roy, Anuja;
Kish, Jonathan K.;
Bloudek, Lisa;
Siegel, David S.;
Jagannath, Sundar;
Globe, Denise;
Kuriakose, Emil T.;
Migliaccio-Walle, Kristen

Publication type:

Article

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

Published in:

Kidney International, 2003, v. 64, n. 1, p. 281, doi. 10.1046/j.1523-1755.2003.00071.x

By:

Markowitz, Glen S.;
Fine, Paul L.;
Stack, Jay I.;
Kunis, Cheryl L.;
Radhakrishnan, Jai;
Palecki, Winicjusz;
Park, Jin;
Nasr, Samih H.;
Hoh, Shirley;
Siegel, David S.;
D'Agati, Vivette D.

Publication type:

Article